RXC007 clinical trials

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

This study is looking into a new medication called RXC007 for Idiopathic Pulmonary Fibrosis (IPF). Researchers want to see if it's safe, how it works in the body, and if it helps patients with IPF. It involves taking the medication or a placebo for 12 weeks.